CXCR3 and myeloid sarcoma: In contrast, in a more recent study, though antibody blockade of CXCL10 reduced intestinal epithelial cell proliferation and CXCR3+ cell migration in vitro and in vivo, it had no significant effect on disease in several preclinical models including IBD, arthritis, and MS [147].